Christopher P. Ouellette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christopher P. Ouellette has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Angelique E Boutzoukas
Department of Pediatrics, Duke University , Durham, North Carolina , USA
2 shared publications- Eunkyung Song
Host Defense Program Division of Infectious Diseases Department of Pediatrics Nationwide Children's Hospital The Ohio State University College of Medicine Columbus Ohio USA
2 shared publications Alejandro Diaz
1 shared publicationAlex Saucedo
Department of Pediatrics, Nationwide Children’s Hospital, Columbus, Ohio
1 shared publicationAmy Leber
Laboratory Medicine, Nationwide Children’s Hospital and The Ohio State University, Columbus
1 shared publication- Andrea Ronchi
Division of Pathology, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
1 shared publication
Latest Publications
- 18 June 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70253
Evaluation of Cytomegalovirus (CMV) T‐Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation
Background: Cytomegalovirus (CMV) is among the most common infectious complications following allogeneic hematopoietic cell transplantation (allo‐HCT). The CMV T‐cell immunity panel (CMV‐TCIP, Viracor) assesses CMV cell‐mediated immunity (CMV‐CMI); however, its utility among pediatric allo‐HCT recipients remains unknown. Methods: A retrospective analysis (January 2020–January 2024) among pediatric (≤ 18 years) allo‐HCT recipients with CMV DNAemia and at least one CMV‐TCIP test was performed. A %CMV‐CD4 + or %CMV‐CD8 + IFN‐γ ≤ 0.2% was categorized as a poor response, whereas a result > 0.2% was classified as adequate. Clinically significant CMV infection (csCMVi) was defined as viral load (VL) ≥ 500 IU/mL. CMV‐TCIP results were compared to CMV VL and the development of csCMVi after allo‐HCT. Results: Twenty‐seven CMV‐TCIP results from 10 allo‐HCT recipients were analyzed. The median age at transplant was 8.5 years (IQR 2.75–14.3), predominantly for hematologic malignancy (70%), and with high‐risk CMV serostatus (R+, 90%). At the time of CMV‐TCIP testing, subjects with a VL < 500 IU/mL had a higher %CMV‐CD4 + IFN‐γ compared to those with a VL ≥ 500 IU/mL (0.36 vs. 0.04, p = 0.02). Peak CMV VLs were lower in those with adequate CD4 + and CD8 + T‐cell responses than in those with poor CD4 + and CD8 + T‐cell responses. In those who received CMV viral‐specific T‐cells (CMV‐VST, n = 5), increased %CD4 + and %CD8 + IFN‐γ responses post‐infusion were observed with a concordant downward trend in VL. Conclusions: Our results demonstrate that the development of CMV‐CMI (particularly CD4 + IFN‐γ > 0.2%) was observed with lower CMV VLs and may provide immunologic insights into pediatric allo‐HCT recipients receiving CMV‐VST.
- 18 June 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70253
Evaluation of Cytomegalovirus (CMV) T‐Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation
Background: Cytomegalovirus (CMV) is among the most common infectious complications following allogeneic hematopoietic cell transplantation (allo‐HCT). The CMV T‐cell immunity panel (CMV‐TCIP, Viracor) assesses CMV cell‐mediated immunity (CMV‐CMI); however, its utility among pediatric allo‐HCT recipients remains unknown. Methods: A retrospective analysis (January 2020–January 2024) among pediatric (≤ 18 years) allo‐HCT recipients with CMV DNAemia and at least one CMV‐TCIP test was performed. A %CMV‐CD4 + or %CMV‐CD8 + IFN‐γ ≤ 0.2% was categorized as a poor response, whereas a result > 0.2% was classified as adequate. Clinically significant CMV infection (csCMVi) was defined as viral load (VL) ≥ 500 IU/mL. CMV‐TCIP results were compared to CMV VL and the development of csCMVi after allo‐HCT. Results: Twenty‐seven CMV‐TCIP results from 10 allo‐HCT recipients were analyzed. The median age at transplant was 8.5 years (IQR 2.75–14.3), predominantly for hematologic malignancy (70%), and with high‐risk CMV serostatus (R+, 90%). At the time of CMV‐TCIP testing, subjects with a VL < 500 IU/mL had a higher %CMV‐CD4 + IFN‐γ compared to those with a VL ≥ 500 IU/mL (0.36 vs. 0.04, p = 0.02). Peak CMV VLs were lower in those with adequate CD4 + and CD8 + T‐cell responses than in those with poor CD4 + and CD8 + T‐cell responses. In those who received CMV viral‐specific T‐cells (CMV‐VST, n = 5), increased %CD4 + and %CD8 + IFN‐γ responses post‐infusion were observed with a concordant downward trend in VL. Conclusions: Our results demonstrate that the development of CMV‐CMI (particularly CD4 + IFN‐γ > 0.2%) was observed with lower CMV VLs and may provide immunologic insights into pediatric allo‐HCT recipients receiving CMV‐VST.
- Open Access
- 3 June 2026
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 53, 100803
Successful salvage treatment of Mucor nidicola and Aspergillus calidoustus co-infection with oral encochleated amphotericin B (MAT2203) in a pediatric patient with acute myeloid leukemia
- 3 June 2026
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 53, 100803
Open AccessSuccessful salvage treatment of Mucor nidicola and Aspergillus calidoustus co-infection with oral encochleated amphotericin B (MAT2203) in a pediatric patient with acute myeloid leukemia
- 7 June 2024
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 13 (8) , 440-442
Acute Histoplasmosis With Pericarditis in Children: A Single-Center Experience
Pericarditis is a potential manifestation of acute histoplasmosis. Noninvasive diagnostics and imaging can be useful in defining a diagnosis. Therapy with itraconazole and corticosteroids was utilized frequently in a cohort with significant effusions at presentation.
- 7 June 2024
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 13 (8) , 440-442
Acute Histoplasmosis With Pericarditis in Children: A Single-Center Experience
Pericarditis is a potential manifestation of acute histoplasmosis. Noninvasive diagnostics and imaging can be useful in defining a diagnosis. Therapy with itraconazole and corticosteroids was utilized frequently in a cohort with significant effusions at presentation.
- 4 October 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14161
Adopting a new approach to treat refractory or resistant viral infections in solid organ transplant recipients
- 4 October 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (6) , e14161
Adopting a new approach to treat refractory or resistant viral infections in solid organ transplant recipients
- Open Access
Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection
Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequent among hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients in absence of antiviral prophylaxis, and is a major cause of morbidity and mortality in these vulnerable populations. Antivirals such ganciclovir, valganciclovir, and foscarnet are the backbone therapies, however drug toxicity and antiviral resistance may render these agents suboptimal in treatment. Newer therapies such as letermovir and maribavir have offered additional approaches for antiviral prophylaxis as well as treatment of drug resistant CMV infection, though may be limited by cost, drug intolerance, or toxicity. Adoptive immunotherapy, the transfer of viral specific T-cells (VSTs), offers a new approach in treatment of drug-resistant or refractory viral infections, with early clinical trials showing promise with respect to efficacy and safety. In this review, we will discuss some of the encouraging results and challenges of widespread adoption of VSTs in care of immunocompromised patients, with an emphasis on the clinical outcomes for treatment and prophylaxis of CMV infection among high-risk patient populations.
Open AccessAdoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection
Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequent among hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients in absence of antiviral prophylaxis, and is a major cause of morbidity and mortality in these vulnerable populations. Antivirals such ganciclovir, valganciclovir, and foscarnet are the backbone therapies, however drug toxicity and antiviral resistance may render these agents suboptimal in treatment. Newer therapies such as letermovir and maribavir have offered additional approaches for antiviral prophylaxis as well as treatment of drug resistant CMV infection, though may be limited by cost, drug intolerance, or toxicity. Adoptive immunotherapy, the transfer of viral specific T-cells (VSTs), offers a new approach in treatment of drug-resistant or refractory viral infections, with early clinical trials showing promise with respect to efficacy and safety. In this review, we will discuss some of the encouraging results and challenges of widespread adoption of VSTs in care of immunocompromised patients, with an emphasis on the clinical outcomes for treatment and prophylaxis of CMV infection among high-risk patient populations.
- 29 July 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (10) , 1841-1842
A Papuloulcerative Rash in an Immunocompetent Child
A 15-year-old female, previously healthy, presents with a 3-week history of progressive lesions to bilateral hands. The lesions began as papular in appearance, although have progressed to include development of new papular lesions as well as mild ulceration of existing lesions. The lesions are nonpainful (with the exception of significant pressure), have scant serous discharge, and are without surrounding erythema ( Figure 1). Over the course of her illness, she received oral amoxicillin/clavulanate without a clinical response noted, and superficial bacterial wound cultures have remained without growth. She has been afebrile during this illness. On exam, she is resting in no acute distress. Her exam is benign apart from bilateral papuloulcerative lesions noted to her hands. Epidemiologic history is notable for living in a rural environment, at home with family members. No other family members have lesions on their hands. No reported gardening activities. She participates in 4H activities,...
- 29 July 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (10) , 1841-1842
A Papuloulcerative Rash in an Immunocompetent Child
A 15-year-old female, previously healthy, presents with a 3-week history of progressive lesions to bilateral hands. The lesions began as papular in appearance, although have progressed to include development of new papular lesions as well as mild ulceration of existing lesions. The lesions are nonpainful (with the exception of significant pressure), have scant serous discharge, and are without surrounding erythema ( Figure 1). Over the course of her illness, she received oral amoxicillin/clavulanate without a clinical response noted, and superficial bacterial wound cultures have remained without growth. She has been afebrile during this illness. On exam, she is resting in no acute distress. Her exam is benign apart from bilateral papuloulcerative lesions noted to her hands. Epidemiologic history is notable for living in a rural environment, at home with family members. No other family members have lesions on their hands. No reported gardening activities. She participates in 4H activities,...
- 24 May 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , e1114-e1122
La Crosse Virus Neuroinvasive Disease in Children: A Contemporary Analysis of Clinical/Neurobehavioral Outcomes and Predictors of Disease Severity
La Crosse virus (LACV) is the most common neuroinvasive arboviral infection in children in the United States. However, data regarding predictors of disease severity and neurologic outcome are limited. Additionally, long-term neurologic and neurobehavioral outcomes remain relatively sparse. This was a single-center, retrospective cohort study, followed by recruitment for a cross-sectional analysis of long-term neurobehavioral outcomes, among children aged 0–18 years with proven or probable LACV neuroinvasive disease (LACV-ND) between January 2009 and December 2018. Case ascertainment was assured by International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification codes cross-referenced with laboratory results detecting LACV. Demographics, diagnostics, radiographs, and outcomes were evaluated. Recruitment of patients with prior diagnosis of LACV-ND occurred from January 2020 to March 2020, with assessment performed by validated pediatric questionnaires. One-hundred fifty-two children (83 males; median age, 8 years [interquartile range, 5–11.5 years]) were diagnosed with proven (n = 61 [47%]) and probable (n = 91 [60%]) LACV-ND. Sixty-five patients (43%) had severe disease. Altered mental status (AMS) (odds ratio [OR], 6.36 [95% confidence interval {CI}, 2.03–19.95]; P = .0002) and seizures at presentation (OR, 10.31 [95% CI, 3.45–30.86]; P = .0001) were independent predictors of severe disease. Epileptiform discharges on electroencephalogram (EEG) were independently associated with epilepsy diagnosis at follow-up (OR, 13.45 [95% CI, 1.4–128.77]; P = .024). Fifty-four patients were recruited for long-term neurobehavioral follow-up, with frequent abnormal assessments identified (19%–54%) irrespective of disease severity. Severe disease was observed frequently among children with LACV-ND. Seizures and AMS at presentation were independent predictors of severe disease. EEG may help determine long-term epilepsy risk. Long-term neurobehavioral issues are frequent and likely underrecognized among children with LACV-ND.
- 24 May 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , e1114-e1122
La Crosse Virus Neuroinvasive Disease in Children: A Contemporary Analysis of Clinical/Neurobehavioral Outcomes and Predictors of Disease Severity
La Crosse virus (LACV) is the most common neuroinvasive arboviral infection in children in the United States. However, data regarding predictors of disease severity and neurologic outcome are limited. Additionally, long-term neurologic and neurobehavioral outcomes remain relatively sparse. This was a single-center, retrospective cohort study, followed by recruitment for a cross-sectional analysis of long-term neurobehavioral outcomes, among children aged 0–18 years with proven or probable LACV neuroinvasive disease (LACV-ND) between January 2009 and December 2018. Case ascertainment was assured by International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification codes cross-referenced with laboratory results detecting LACV. Demographics, diagnostics, radiographs, and outcomes were evaluated. Recruitment of patients with prior diagnosis of LACV-ND occurred from January 2020 to March 2020, with assessment performed by validated pediatric questionnaires. One-hundred fifty-two children (83 males; median age, 8 years [interquartile range, 5–11.5 years]) were diagnosed with proven (n = 61 [47%]) and probable (n = 91 [60%]) LACV-ND. Sixty-five patients (43%) had severe disease. Altered mental status (AMS) (odds ratio [OR], 6.36 [95% confidence interval {CI}, 2.03–19.95]; P = .0002) and seizures at presentation (OR, 10.31 [95% CI, 3.45–30.86]; P = .0001) were independent predictors of severe disease. Epileptiform discharges on electroencephalogram (EEG) were independently associated with epilepsy diagnosis at follow-up (OR, 13.45 [95% CI, 1.4–128.77]; P = .024). Fifty-four patients were recruited for long-term neurobehavioral follow-up, with frequent abnormal assessments identified (19%–54%) irrespective of disease severity. Severe disease was observed frequently among children with LACV-ND. Seizures and AMS at presentation were independent predictors of severe disease. EEG may help determine long-term epilepsy risk. Long-term neurobehavioral issues are frequent and likely underrecognized among children with LACV-ND.
- 11 January 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (2) , 172-174
Fever of Unknown Origin in a 6-Year-old
- 11 January 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (2) , 172-174
Fever of Unknown Origin in a 6-Year-old
- 16 January 2021
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 10 (5) , 698-701
Disseminated Toxoplasmosis in a Child Following Allogeneic Hematopoietic Cell Transplantation
A 23-month old female with hypoplastic myelodysplastic syndrome underwent allogenic hematopoietic cell transplantation (HCT), complicated by development of acute exotropia. Bilateral chorioretinal scars and a ring enhancing brain lesion were identified in further workup. Disseminated toxoplasmosis post-allogeneic HCT was subsequently confirmed by serologic and polymerase chain reaction testing results.
- 16 January 2021
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 10 (5) , 698-701
Disseminated Toxoplasmosis in a Child Following Allogeneic Hematopoietic Cell Transplantation
A 23-month old female with hypoplastic myelodysplastic syndrome underwent allogenic hematopoietic cell transplantation (HCT), complicated by development of acute exotropia. Bilateral chorioretinal scars and a ring enhancing brain lesion were identified in further workup. Disseminated toxoplasmosis post-allogeneic HCT was subsequently confirmed by serologic and polymerase chain reaction testing results.
- 1 November 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (11) , 2781-2783
Osteomyelitis Due to Mycobacterium goodii in an Adolescent, United States
Osteomyelitis is a rare clinical manifestation of infection with nontuberculous mycobacteria (NTM). We report an adolescent with femoral osteomyelitis associated with prosthetic material due to an emerging pathogen, Mycobacterium goodii. Application of secA1 and 16S ribosomal RNA gene sequencing reliably determined the NTM species, enabling targeted antimicrobial therapy.
- 1 November 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (11) , 2781-2783
Osteomyelitis Due to Mycobacterium goodii in an Adolescent, United States
Osteomyelitis is a rare clinical manifestation of infection with nontuberculous mycobacteria (NTM). We report an adolescent with femoral osteomyelitis associated with prosthetic material due to an emerging pathogen, Mycobacterium goodii. Application of secA1 and 16S ribosomal RNA gene sequencing reliably determined the NTM species, enabling targeted antimicrobial therapy.